Showing posts with label Amputations. Show all posts
Showing posts with label Amputations. Show all posts

Thursday, 8 March 2018

Antidiabetics Market to grow at 10.5% CAGR from 2017 to 2024

Antidiabetics Market growth is driven by rising geriatric population base, innovation of new drugs, increasing adoption of drugs and increased disposable income. Owing to the changes in lifestyle, even children between age group of 13-14 years are at high risk to get diabetes. It offers huge opportunities industry players. Antidiabetics Market size is set to reach USD 110 billion by 2024; according to a new research report by Global Market Insights, Inc.

Increasing number of obese and diabetic patients coupled with rising patient awareness levels serve as high impact rendering factors for antidiabetic market growth over the forecast period. 

Request for a sample of this research report - https://www.gminsights.com/request-sample/detail/504

Favorable government initiatives such as Diabetes Prevention Program (DPP) that aims to help individuals with prediabetes, reduces their risk to develop type 2 diabetes. Trained lifestyle coach works with participants and communicate lifestyle skills, such as, eating healthy food, physical activity and managing stress. Such initiatives should propel industry growth over the forecast period. 
Advent of new technologies in products like long acting insulin analogs as well as rapid acting with increased effectiveness should drive industry growth over the forecast timeframe. The novel insulin pen technology permits low-pain and suitable daily insulin injection that should upsurge therapy sales. Type 2 diabetes mellitus (T2DM) has strong familial aggregation, the person with a parent or sibling with disease are at high risk. People with obesity, hypertension, or dyslipidemia and women with history of gestational diabetes are also at high risk to develop T2DM.

Browse key industry insights spread across 130 pages with 55 market data tables & 8 figures & charts from the report Antidiabetics Market in detail along with the table of contents:


Long-acting insulin provide basal insulin coverage. Basal insulin suppresses hepatic gluconeogenesis and prevent increase in glucose level during fasting state in insulin-deficient patients.  Long acting insulin analog includes insulin glargine (Lantus) and insulin detemir (Levemir) which will drive industry growth.

Biguanides should contribute for significant revenue share in 2016. It is colorless solid and prevents production of glucose in liver. Biguanides are administered orally for the treatment of type 2 diabetes. It helps in improving sensitivity of body towards insulin and decreases amount of sugar absorbed in intestines and will increase demand for such antidiabetic drugs.

U.S. antidiabetics market size valued over USD 19.4 billion in 2016 and expected to grow significantly over the coming years. Increased healthcare expenditure along with availability of improved healthcare infrastructure and favorable reimbursement policies should drive antidiabetics market size. 

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/504

UK contributed for significant revenue share in 2016. The growth is attributed due to wide range of funds offered by Diabetes UK for research related to the treatment of diabetes and its complications. In November 2016, the Prime Minister introduced new Diabetes UK office on World Diabetes Day. 

Japan antidiabetics market should grow at significant rate over the forecast period. Diabetic population is on rise due to lifestyle changes that will accompany economic growth and drive antidiabetic market growth. The Japan Diabetes Society (JDS) encourage progress and development of diabetes study and prevent people from disease in the country.

Brazil contributed for significant revenue share. The growth is attributed due to early adoption of insulin analogues and increased use of these products in the country.

Some of the companies operating in antidiabetics market include Eli Lilly, Pfizer, Novo Nordisk, Takeda Pharmaceuticals, Sanofi Aventis, Merck, Boehringer Ingelheim and Oramed Pharmaceuticals.

Browse Related Reports:

Precision Medicine Market Size By Technology (Big Data Analytics, Gene Sequencing, Drug Discovery, Bioinformatics, Companion Diagnostics), By Application (Oncology, CNS, Immunology, Respiratory), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Scandinavia, Italy, Japan, China, India, Singapore, Mexico, Brazil, South Africa, UAE, Qatar, Saudi Arabia), Application Potential, Price Trends, Competitive Market Share & Forecast, 2016 – 2023


About Global Market Insights:

Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.


Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email:
sales@gminsights.com
Web: https://www.gminsights.com
Blog: https://gminsights.wordpress.com
Connect with us: Facebook | Google+ | LinkedIn | Twitter
Explore Our Blog @ http://algosonline.com/news

Monday, 13 November 2017

Antidiabetics Market share to grow at 10.5% CAGR from 2016 to 2024

Inherently propelled by a stringent regulatory framework, antidiabetics market is strongly characterized by the legalized norms implemented by authorized bodies such as the European CE and the FDA. Having undertaken the crucial responsibility of regulating the commercialization of antidiabetics in clinical trials, these organizations continue to strive hard to approve drugs post their testing with utmost caution and precision, which is a prime factor driving the growth of antidiabetics industry. For instance, recently, the U.S. Food and Drug Administration approved the Bydureon BCise (exenatide extended-release) injectable suspension manufactured by AstraZeneca.

Apparently, this drug is an all-new formulation of Bydureon that is available as a single-dose autoinjector device for adults suffering from Type II diabetes. The Bydureon BCise apparently underwent two clinical trials prior to obtaining the approval, thus validating the fact that antidiabetics market outlook is strictly defined by a regulatory frame of reference.

Request for a sample of this research report - https://www.gminsights.com/request-sample/detail/504

With the exponentially growing population and the prevalence of a sedentary lifestyle, a significant rise in the patient pool suffering from diabetes has been observed, which is likely to spur global antidiabetics market share. The WHO estimates that diabetes would be among the leading causes of death by 2030, which would severely strain the overall healthcare fraternity. The rising number of diabetic cases have prompted the governments across various geographies to take steps toward promoting awareness regarding this disorder. For instance, the ‘Diabetes UK’ is slated to launch one of the biggest campaigns to encourage consciousness regarding Type II diabetes.

The program will also make people aware of the harmful consequences of developing diabetes, encourage them to get screened regularly, and provide other related details. The prevalence of campaigns and awareness programs such as the aforementioned are certain to bring about a positive influence on antidiabetics market size, which was pegged at USD 49.5 billion in 2016.

Browse key industry insights spread across 130 pages with 55 market data tables & 8 figures & charts from the report Antidiabetics Market in detail along with the table of contents:


In consequence to the unmet medical requirements of the healthcare fraternity and the rapid increase in the diabetic patient base, antidiabetics industry players have been concentrating on increasing their funding on research & development activities with an aim to launch novel insulin products that will efficiently treat this persistent sugar disorder. Major companies such as Sanofi Aventis, Eli Lilly, and Novo Nordisk presently predominate antidiabetic market share, pertaining to their popular brand value, wide range of products, and increased R&D investments. Many antidiabetics products that are currently in the pipeline to be commercialized are manufactured by these companies. In addition, global antidiabetics industry involves the participation of other generic manufacturers such as Pfizer, Oramed Pharmaceuticals, Inc., Takeda Pharmaceuticals, Boehringer Ingelheim, and Merck & Co. Inc.

An insight into APAC antidiabetics market trends:

The Asia Pacific region has been forecast to emerge as the potential hotbed for investors emptying their coffers in antidiabetics industry. This estimation may be attributed to the fact that the region has been witnessing a tremendous surge in the patient pool suffering from diabetes, especially in India and China. As per reliable statistics, close to nearly two decades earlier, in 2000, India stood at the top of the pyramid representing diabetes sufferers, with more than 31.7 million of its populace afflicted by the disease, while China stood at the second place with 20.8 million diabetic patients in tow. It has been forecast that by 2030, this number would increase up to 79.4 million patients in India and 42.3 million individuals in China. The estimates stand to validate that these countries would prove to be lucrative grounds for companies partaking in antidiabetics market share, as they would be able to bring forth a range of medications for treating the affliction in these regions.

Another emerging region in this continent has been touted to be Japan. The country, with its incredible healthcare infrastructure, rising penetration of technologically innovative insulin drugs, and the growing prevalence of diabetes among the geriatric populace, will serve to be a profitable growth avenue for APAC antidiabetics market.

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/504

Regulatory and governmental bodies across the globe have been striving to increase public awareness regarding diabetes, which most certainly would provide an impetus to antidiabetics market. For instance, the National Institute of Diabetes and Digestive and Kidney Diseases has undertaken several education campaigns such as ‘Small Steps, Big Rewards’, ‘Control your Diabetes for Life’, etc., to increase the importance of diabetic screening, diagnosis, and treatment. Not far behind in the list of organizations is the American Diabetes Association, that has also launched several awareness programs regarding diabetes, which would help carve out a lucrative growth path for global antidiabetics market over the years ahead. In addition, the International Diabetes Federation, along with its member associations celebrate the 14th of November as ‘World Diabetes Day’, utilizing the 24-hour span to initiate awareness campaigns and other related programs. With a strong regulatory framework and governmental support in place, not to mention, the pivotal developments underlining the medical research and healthcare verticals, it is forecast that antidiabetics industry will chart a profitable growth curve over the coming seven years, with an estimated valuation of USD 110 billion by 2024.


Precision Medicine Market Size By Technology (Big Data Analytics, Gene Sequencing, Drug Discovery, Bioinformatics, Companion Diagnostics), By Application (Oncology, CNS, Immunology, Respiratory), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Scandinavia, Italy, Japan, China, India, Singapore, Mexico, Brazil, South Africa, UAE, Qatar, Saudi Arabia), Application Potential, Price Trends, Competitive Market Share & Forecast, 2016 – 2023


About Global Market Insights:

Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.


Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email:
sales@gminsights.com
Web: https://www.gminsights.com
Blog: https://gminsights.wordpress.com
Connect with us: Facebook | Google+ | LinkedIn | Twitter